291 related articles for article (PubMed ID: 35879733)
1. YKL-40 changes are not detected in post-mortem brain of patients with Alzheimer's disease and frontotemporal lobar degeneration.
Hok-A-Hin YS; Hoozemans JJM; Hu WT; Wouters D; Howell JC; Rábano A; van der Flier WM; Pijnenburg YAL; Teunissen CE; Del Campo M
Alzheimers Res Ther; 2022 Jul; 14(1):100. PubMed ID: 35879733
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein L1 is increased in frontotemporal lobar degeneration post-mortem brain but not in ante-mortem cerebrospinal fluid.
Hok-A-Hin YS; Dijkstra AA; Rábano A; Hoozemans JJ; Castillo L; Seelaar H; van Swieten JC; Pijnenburg YAL; Teunissen CE; Del Campo M
Neurobiol Dis; 2022 Oct; 172():105813. PubMed ID: 35820647
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype.
Woollacott IOC; Nicholas JM; Heller C; Foiani MS; Moore KM; Russell LL; Paterson RW; Keshavan A; Schott JM; Warren JD; Heslegrave A; Zetterberg H; Rohrer JD
Dement Geriatr Cogn Disord; 2020; 49(1):56-76. PubMed ID: 32344399
[TBL] [Abstract][Full Text] [Related]
4. Elevated YKL-40 and low sAPPβ:YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD.
Alcolea D; Irwin DJ; Illán-Gala I; Muñoz L; Clarimón J; McMillan CT; Fortea J; Blesa R; Lee EB; Trojanowski JQ; Grossman M; Lleó A
J Neurol Neurosurg Psychiatry; 2019 Feb; 90(2):180-186. PubMed ID: 30297518
[TBL] [Abstract][Full Text] [Related]
5. CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration.
Alcolea D; Vilaplana E; Suárez-Calvet M; Illán-Gala I; Blesa R; Clarimón J; Lladó A; Sánchez-Valle R; Molinuevo JL; García-Ribas G; Compta Y; Martí MJ; Piñol-Ripoll G; Amer-Ferrer G; Noguera A; García-Martín A; Fortea J; Lleó A
Neurology; 2017 Jul; 89(2):178-188. PubMed ID: 28592456
[TBL] [Abstract][Full Text] [Related]
6. CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia.
Abu-Rumeileh S; Steinacker P; Polischi B; Mammana A; Bartoletti-Stella A; Oeckl P; Baiardi S; Zenesini C; Huss A; Cortelli P; Capellari S; Otto M; Parchi P
Alzheimers Res Ther; 2019 Dec; 12(1):2. PubMed ID: 31892365
[TBL] [Abstract][Full Text] [Related]
7. Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration.
Irwin DJ; Lleó A; Xie SX; McMillan CT; Wolk DA; Lee EB; Van Deerlin VM; Shaw LM; Trojanowski JQ; Grossman M
Ann Neurol; 2017 Aug; 82(2):247-258. PubMed ID: 28719018
[TBL] [Abstract][Full Text] [Related]
8. Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer's disease brains: Implications for in-vivo diagnostics.
den Haan J; Morrema THJ; Rozemuller AJ; Bouwman FH; Hoozemans JJM
Acta Neuropathol Commun; 2018 Aug; 6(1):75. PubMed ID: 30092839
[TBL] [Abstract][Full Text] [Related]
9. Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration.
Cervantes González A; Irwin DJ; Alcolea D; McMillan CT; Chen-Plotkin A; Wolk D; Sirisi S; Dols-Icardo O; Querol-Vilaseca M; Illán-Gala I; Santos-Santos MA; Fortea J; Lee EB; Trojanowski JQ; Grossman M; Lleó A; Belbin O
Mol Neurodegener; 2022 Apr; 17(1):29. PubMed ID: 35395770
[TBL] [Abstract][Full Text] [Related]
10. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.
Craig-Schapiro R; Perrin RJ; Roe CM; Xiong C; Carter D; Cairns NJ; Mintun MA; Peskind ER; Li G; Galasko DR; Clark CM; Quinn JF; D'Angelo G; Malone JP; Townsend RR; Morris JC; Fagan AM; Holtzman DM
Biol Psychiatry; 2010 Nov; 68(10):903-12. PubMed ID: 21035623
[TBL] [Abstract][Full Text] [Related]
11. Plasma proteome profiling identifies changes associated to AD but not to FTD.
Mofrad RB; Del Campo M; Peeters CFW; Meeter LHH; Seelaar H; Koel-Simmelink M; Ramakers IHGB; Middelkoop HAM; De Deyn PP; Claassen JAHR; van Swieten JC; Bridel C; Hoozemans JJM; Scheltens P; van der Flier WM; Pijnenburg YAL; Teunissen CE
Acta Neuropathol Commun; 2022 Oct; 10(1):148. PubMed ID: 36273219
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid Aβ40 is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease.
Baldeiras I; Santana I; Leitão MJ; Ribeiro MH; Pascoal R; Duro D; Lemos R; Santiago B; Almeida MR; Oliveira CR
J Neurol Sci; 2015 Nov; 358(1-2):308-16. PubMed ID: 26388316
[TBL] [Abstract][Full Text] [Related]
13. Frontotemporal lobar degeneration FTLD-tau: preclinical lesions, vascular, and Alzheimer-related co-pathologies.
Thal DR; von Arnim CA; Griffin WS; Mrak RE; Walker L; Attems J; Arzberger T
J Neural Transm (Vienna); 2015 Jul; 122(7):1007-18. PubMed ID: 25556950
[TBL] [Abstract][Full Text] [Related]
14. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration.
Ishiki A; Kamada M; Kawamura Y; Terao C; Shimoda F; Tomita N; Arai H; Furukawa K
J Neurochem; 2016 Jan; 136(2):258-61. PubMed ID: 26485083
[TBL] [Abstract][Full Text] [Related]
15. A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes.
Lleó A; Irwin DJ; Illán-Gala I; McMillan CT; Wolk DA; Lee EB; Van Deerlin VM; Shaw LM; Trojanowski JQ; Grossman M
JAMA Neurol; 2018 Jun; 75(6):738-745. PubMed ID: 29554190
[TBL] [Abstract][Full Text] [Related]
16. Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer's Disease from Frontotemporal Lobar Degeneration.
Ortner M; Goldhardt O; Diehl-Schmid J; Yakushev I; Lanz K; Hedderich DM; Manuilova E; Simon M; Weinberger JP; Grimmer T
J Prev Alzheimers Dis; 2022; 9(3):491-498. PubMed ID: 35841250
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study.
Abu-Rumeileh S; Mometto N; Bartoletti-Stella A; Polischi B; Oppi F; Poda R; Stanzani-Maserati M; Cortelli P; Liguori R; Capellari S; Parchi P
J Alzheimers Dis; 2018; 66(2):551-563. PubMed ID: 30320576
[TBL] [Abstract][Full Text] [Related]
18. Relationship of serum beta-synuclein with blood biomarkers and brain atrophy.
Oeckl P; Anderl-Straub S; Danek A; Diehl-Schmid J; Fassbender K; Fliessbach K; Halbgebauer S; Huppertz HJ; Jahn H; Kassubek J; Kornhuber J; Landwehrmeyer B; Lauer M; Prudlo J; Schneider A; Schroeter ML; Steinacker P; Volk AE; Wagner M; Winkelmann J; Wiltfang J; Ludolph AC; Otto M;
Alzheimers Dement; 2023 Apr; 19(4):1358-1371. PubMed ID: 36129098
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration.
Goossens J; Bjerke M; Van Mossevelde S; Van den Bossche T; Goeman J; De Vil B; Sieben A; Martin JJ; Cras P; De Deyn PP; Van Broeckhoven C; van der Zee J; Engelborghs S
Alzheimers Res Ther; 2018 Mar; 10(1):31. PubMed ID: 29559004
[TBL] [Abstract][Full Text] [Related]
20. TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration.
Buciuc M; Martin PR; Tosakulwong N; Murray ME; Petrucelli L; Senjem ML; Spychalla AJ; Knopman DS; Boeve BF; Petersen RC; Parisi JE; Reichard RR; Dickson DW; Jack CR; Whitwell JL; Josephs KA
Neuroimage Clin; 2022; 34():102954. PubMed ID: 35168140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
